Player FM - Internet Radio Done Right
Checked 2d ago
two 年前 前追加した
コンテンツは touchpodcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、touchpodcast またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
聞く価値のあるポッドキャスト
スポンサード
M
Mind The Business: Small Business Success Stories
![Mind The Business: Small Business Success Stories podcast artwork](https://cdn.player.fm/images/44159763/series/yvoDOHutf1eKJqQp/32.jpg 32w, https://cdn.player.fm/images/44159763/series/yvoDOHutf1eKJqQp/64.jpg 64w, https://cdn.player.fm/images/44159763/series/yvoDOHutf1eKJqQp/128.jpg 128w, https://cdn.player.fm/images/44159763/series/yvoDOHutf1eKJqQp/256.jpg 256w, https://cdn.player.fm/images/44159763/series/yvoDOHutf1eKJqQp/512.jpg 512w)
![Mind The Business: Small Business Success Stories podcast artwork](/static/images/64pixel.png)
1 The SB Starter Kit - Everything You Need or Need to Know to Get Your Business Off the Ground (Part 1) - Trademarks, Patents, LLCs and SCorps 35:28
35:28
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った35:28![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Step one for starting a small business is often coming up with an exciting idea. But what is step two? Step three? Steps four through launch and beyond? On our second episode, and first iteration of our Small Business Starter Kit Series, Austin and Jannese visit The Candle Pour to chat with founders Misty and Dennis Akers . They’ll tell our hosts about how they got their business off the ground and about all the things that go with it: from incorporation to trademarks. Join us as they detail how they went from Grand Idea to Grand Opening. Learn more about how QuickBooks can help you grow your business: Quickbooks.com See omnystudio.com/listener for privacy information.…
touchPODCAST
すべての項目を再生済み/未再生としてマークする
Manage series 3389426
コンテンツは touchpodcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、touchpodcast またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
…
continue reading
102 つのエピソード
すべての項目を再生済み/未再生としてマークする
Manage series 3389426
コンテンツは touchpodcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、touchpodcast またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
…
continue reading
102 つのエピソード
すべてのエピソード
×![Artwork](/static/images/128pixel.png)
1 Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57
55:57
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った55:57![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchCONGRESS for ONCOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/…
![Artwork](/static/images/128pixel.png)
1 Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57
55:57
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った55:57![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchCONGRESS for touchHAEMATOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/…
![Artwork](/static/images/128pixel.png)
1 RAS mutations and personalized cancer care: Targeting the future 31:02
31:02
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った31:02![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchONCOLOGY Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes. The experts Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines . This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mutations-and-personalized-cancer-care-targeting-the-future/…
![Artwork](/static/images/128pixel.png)
1 What’s new in primary ITP? Key updates from ASH 2024 40:35
40:35
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った40:35![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchPANEL DISCUSSION for touchONCOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition. The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#…
![Artwork](/static/images/128pixel.png)
1 What’s new in primary ITP? Key updates from ASH 2024 40:35
40:35
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った40:35![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchPANEL DISCUSSION for touchHAEMATOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition. The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#…
![Artwork](/static/images/128pixel.png)
1 Focused insights: Data implications of ADCs in NSCLC treatment 21:54
21:54
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った21:54![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchFOCUS for touchRESPIRATORY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchrespiratory.org/ADCs-in-NSCLC…
![Artwork](/static/images/128pixel.png)
1 Focused insights: Data implications of ADCs in NSCLC treatment 21:54
21:54
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った21:54![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchFOCUS for touchONCOLOGY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchoncology.org/ADCs-in-NSCLC…
![Artwork](/static/images/128pixel.png)
1 Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGY 1:20:58
1:20:58
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った1:20:58![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchSYMPOSIUM for touchHAEMATOLOGY Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA. Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies. Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current management strategies Session 3: Prof. David Kuter reviews emerging targeted treatment options for ITP, with a focus on their mechanisms of action and the latest data Session 4: A panel discussion with all three faculty on shared decision-making and collaboration in the clinic This touchPODCAST is for HCPs in the USA. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchoncologyime.org…
![Artwork](/static/images/128pixel.png)
1 Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchHAEMATOLOGY 1:20:58
1:20:58
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った1:20:58![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchSYMPOSIUM for touchHAEMATOLOGY Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA. Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies. Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current management strategies Session 3: Prof. David Kuter reviews emerging targeted treatment options for ITP, with a focus on their mechanisms of action and the latest data Session 4: A panel discussion with all three faculty on shared decision-making and collaboration in the clinic This touchPODCAST is for HCPs in the USA. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchhaematologyime.org…
![Artwork](/static/images/128pixel.png)
1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37
37:37
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った37:37![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT FOCUS for touchONCOLOGY Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered. The experts Dr AeRang Kim, Children's National Hospital, Washington, DC, USA Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Springworks Therapeutics, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/expert-focus-management-of-nf1/…
![Artwork](/static/images/128pixel.png)
1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38
37:38
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った37:38![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT FOCUS for touchNEUROLOGY Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered. The experts Dr AeRang Kim, Children's National Hospital, Washington, DC, USA Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Springworks Therapeutics, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchneurologyime.org/expert-focus-management-of-nf1/…
![Artwork](/static/images/128pixel.png)
1 Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15
38:15
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った38:15![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchONCOLOGY Listen to an oncologist, urologist and oncology nurse highlight the key data for immunotherapy in the perioperative setting for muscle-invasive bladder cancer, practical considerations for its use in clinical practice, and how possible side effects can be monitored for and managed. They also consider the role of the multidisciplinary team in implementing this treatment modality. The experts Dr Laura Mertens, Netherlands Cancer Institute, Amsterdam, The Netherlands Prof. Thomas Powles, Barts Cancer Centre, London, UK Ms Lindsay Diamond, Icahn School of Medicine at Mount Sinai, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…
![Artwork](/static/images/128pixel.png)
1 Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY 34:20
34:20
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った34:20![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchDERMATOLOGY Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions. The experts Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Dr Teresa Amaral, Tübingen University, Tübingen, Germany This touchPODCAST is for healthcare professionals outside of the UK only This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchdermaime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma…
![Artwork](/static/images/128pixel.png)
1 Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY 34:19
34:19
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った34:19![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchONCOLOGY Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions. The experts Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Dr Teresa Amaral, Tübingen University, Tübingen, Germany This touchPODCAST is for healthcare professionals outside of the UK only This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma…
![Artwork](/static/images/128pixel.png)
1 Advances in IOL technology and power calculations: Updates and innovations from 2024 13:58
13:58
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った13:58![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchFOCUS for touchOPHTHALMOLOGY Listen to Dr John Ladas, an expert in cataract surgery, as he answers a series of questions on intraocular lens power calculation, including how the use of artificial intelligence may help to improve accuracy, and provides an update on the latest advances in intraocular lens technology. The expert Dr John Ladas, Maryland Eye Consultants & Surgeons, Silver Spring, MD, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Johnson & Johnson Surgical Vision, Inc. and Carl Zeiss Meditec, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchophthalmology.com/…
![Artwork](/static/images/128pixel.png)
1 Supporting healing in epidermolysis bullosa: Innovations and new directions for care 18:55
18:55
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った18:55![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchFOCUS for touchDERMATOLOGY Listen to Prof. Amy Paller as she answers a series of questions on the key features of epidermolysis bullosa, including its pathophysiology and clinical manifestations. In addition, she responds to questions on the role of new and emerging topical therapies for epidermolysis bullosa in patient care, with a focus on a multidisciplinary team approach . The expert: Prof. Amy Paller - Northwestern University Feinberg School of Medicine, Chicago, IL, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from Chiesi USA Inc . This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchDERMA.com…
![Artwork](/static/images/128pixel.png)
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
35:31
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った35:31![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchIMMUNOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis. The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME . For further information visit our website: https://touchimmunologyime.org/Primary-biliary-cholangitis-therapeutic-landscape…
![Artwork](/static/images/128pixel.png)
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
35:31
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った35:31![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis. The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchendocrinologyime.org/p rimary-biliary-cholangitis-therapeutic-landscape…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
13:46
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った13:46![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchONCOLOGY.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
16:05
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った16:05![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchONCOLOGY.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
13:46
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った13:46![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchRESPIRATORY.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
16:05
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った16:05![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchRESPIRATORY.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14
15:14
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った15:14![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchRESPIRATORY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects. The multidisciplinary team Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands Pulmonologist – Dr Lizza Hendriks, Maastricht University Medical Center, Maastricht, The Netherlands Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/…
![Artwork](/static/images/128pixel.png)
1 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57
13:57
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った13:57![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchRESPIRATORY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/…
![Artwork](/static/images/128pixel.png)
1 touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 14:53
14:53
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った14:53![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchRESPIRATORY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC. The multidisciplinary team: Pulmonologist – Dr Lizza Hendriks, Maastricht University Medical Center, Maastricht, The Netherlands Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/…
![Artwork](/static/images/128pixel.png)
1 touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14
15:14
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った15:14![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchONCOLOGY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects. The multidisciplinary team Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands Pulmonologist – Dr Lizza Hendriks, Maastricht University Medical Center, Maastricht, The Netherlands Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/…
![Artwork](/static/images/128pixel.png)
1 touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57
13:57
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った13:57![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchONCOLOGY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/…
![Artwork](/static/images/128pixel.png)
1 touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 14:53
14:53
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った14:53![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchONCOLOGY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC. The multidisciplinary team: Pulmonologist – Dr Lizza Hendriks, Maastricht University Medical Center, Maastricht, The Netherlands Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/…
![Artwork](/static/images/128pixel.png)
1 Vaccination strategies for pneumococcal disease 33:06
33:06
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った33:06![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchINFECTIOUS DISEASES In this activity, Prof. Antoni Torres, a leading expert in respiratory infections, discusses the burden of pneumococcal disease in vulnerable patient populations, the evolving landscape of Streptococcus pneumoniae subtypes and the role that next-generation vaccines can play in preventing severe pneumococcal infections. The expert Prof. Antoni Torres, University of Barcelona, Spain This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck Sharp & Dohme LLC . This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchINFECTIOUS DISEASES.com…
![Artwork](/static/images/128pixel.png)
1 Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024 52:36
52:36
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った52:36![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchCONGRESS for touchONCOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line setting Approved and emerging TKIs for CML in the second- and later-line settings Potential impact of emerging data on current and future clinical practice The internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, Italy Prof. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan . This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. For further information visit our website: TBC…
![Artwork](/static/images/128pixel.png)
1 Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024 52:36
52:36
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った52:36![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchCONGRESS for touchHAEMATOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line setting Approved and emerging TKIs for CML in the second- and later-line settings Potential impact of emerging data on current and future clinical practice The internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, Italy Prof. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan . This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. For further information visit our website: TBC…
![Artwork](/static/images/128pixel.png)
1 Pharmacological management of agitation in Alzheimer's dementia 34:28
34:28
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った34:28![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology. The experts Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA Prof. Krista Lanctôt, University of Toronto, ON, Canada Prof. James Galvin, University of Miami, FL, USA This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Lundbeck. This activity is jointly provided by USF Health and touchIME in collaboration with the Gerontological Society of America (GSA). For further information visit: https://touchneurologyime.org/cme/curriculums/agitation-in-alzheimers-dementia/…
![Artwork](/static/images/128pixel.png)
1 touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORY 35:33
35:33
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った35:33![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchIN CONVERSATION for touchRESPIRATORY Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium For further information visit our website: www.touchRESPIRATORY.com…
![Artwork](/static/images/128pixel.png)
1 touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIO 35:33
35:33
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った35:33![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchIN CONVERSATION for touchCARDIO Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium For further information visit our website: www.touchCARDIO.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 14:12
14:12
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った14:12![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchONCOLOGY.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 15:59
15:59
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った15:59![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchONCOLOGY.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 14:12
14:12
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った14:12![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchRESPIRATORY.com…
![Artwork](/static/images/128pixel.png)
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 15:59
15:59
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った15:59![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchRESPIRATORY.com…
![Artwork](/static/images/128pixel.png)
1 Targets in early NSCLC: A focus on EGFR-mutant treatment options 16:22
16:22
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った16:22![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchFOCUS for touchONCOLOGY Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testing and the importance of multidisciplinary care for optimizing outcomes in these patients. The expert Dr Jennifer Carlisle, Winship Cancer Institute of Emory University, Atlanta, GA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchoncology.org/EGFR-mutant-treatment-options-early-NSCLC…
![Artwork](/static/images/128pixel.png)
1 Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024 57:31
57:31
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った57:31![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchCONGRESS for touchONCOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mateos, Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below Clinical themes Approved indications for BCMA-targeting agents, New approaches to the use of existing BCMA-targeting agents, Emerging BCMA-targeting agents The internationally renowned multiple myeloma expert faculty Prof. María-Victoria Mateos: Salamanca, Spain, Dr Rakesh Popat: London, UK, Prof. Evangelos Terpos: Athens, Greece This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/bcma-mm-comy-eha-2024…
![Artwork](/static/images/128pixel.png)
1 Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024 57:31
57:31
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った57:31![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchCONGRESS for touchHAEMATOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mateos, Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below Clinical themes Approved indications for BCMA-targeting agents, New approaches to the use of existing BCMA-targeting agents, Emerging BCMA-targeting agents The internationally renowned multiple myeloma expert faculty Prof. María-Victoria Mateos: Salamanca, Spain, Dr Rakesh Popat: London, UK, Prof. Evangelos Terpos: Athens, Greece This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/bcma-mm-comy-eha-2024…
![Artwork](/static/images/128pixel.png)
1 Innovations in glaucoma care: Targeting pathophysiology to expand treatment options 33:45
33:45
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った33:45![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchEXPERT OPINIONS for touchOPHTHALMOLOGY Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice. The experts Angelo P Tanna, MD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA Courtney E Bovee, MD - Bovee Eye, Tampa Bay, FL, USA Joseph F Panarelli, MD - NYU Langone Eye Center, New York, NY, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Alcon Vision, LLC and is jointly provided by USF Health and touchIME. For further information visit our website: https://touchOPHTHALMOLOGY.com/…
![Artwork](/static/images/128pixel.png)
1 Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents 40:07
40:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った40:07![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchIN CONVERSATION for touchIMMUNOLOGY Listen to Prof. Diamant Thaçi in conversation with Dr Benjamin Ungar. They respond to questions submitted by the HCP audience and provide their expert insights regarding managing moderate–severe atopic dermatitis (AD) in children and adolescents, including assessing the severity of AD, selecting systemic therapy, and managing the potential side effects of systemic treatment. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals and is jointly provided by USF Health and touchIME. For further information visit our website: touchimmunology.com…
![Artwork](/static/images/128pixel.png)
1 Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents 40:07
40:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った40:07![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchIN CONVERSATION for touchDERMATOLOGY Listen to Prof. Diamant Thaçi in conversation with Dr Benjamin Ungar. They respond to questions submitted by the HCP audience and provide their expert insights regarding managing moderate–severe atopic dermatitis (AD) in children and adolescents, including assessing the severity of AD, selecting systemic therapy, and managing the potential side effects of systemic treatment. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals and is jointly provided by USF Health and touchIME. For further information visit our website: touchderma.com…
![Artwork](/static/images/128pixel.png)
1 Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors 18:41
18:41
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った18:41![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
touchFOCUS for touchONCOLOGY Listen to Prof. Barbara Burtness as she answers a series of questions focused on the evolving role of immune checkpoint inhibitors in the first- and subsequent-line settings for recurrent/metastatic nasopharyngeal carcinoma. The expert Prof. Barbara Burtness, Yale School of Medicine, New Haven, CT, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Coherus BioSciences. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/touchfocus_evolving-role-of-icis-in-rm-npc/…
プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。